AME BIOSCIENCE AS
Score · fiscal year 2025
76of 100
How to read this: the company is ahead of 94 % of companies in the Morning class Small in the same sector in 2025. What does this mean?
Rank in the Morning class Small: 438 of 7,421 · What are Morning company classes?
Place in the whole sector: 1,433 of 23,059 · Handel
Profile
Lion · Leader
High profitability, high solidity
Position against comparable companies in 2025, not a verdict on the company. Based on profitability 91 and solidity 89 out of 100 among companies in the Morning class Small in the same sector in 2025. Methodology
Against the sector
AME BIOSCIENCE AS is 25 points above the median for companies in the Morning class Small in the same sector in 2025.
Median score 51 among 7,421 companies.
Against companies in the Morning class Small in the same sector in 2025: operating margin 20.2% (median 3.4%) and equity ratio 73.9% (median 36.3%).
The numbers behind the score
| Measure | Company | Median |
|---|---|---|
| Operating revenue | 18 MNOK | 20 MNOK |
| Operating margin | 20.2% | 3.4% |
| Profit margin | 20.0% | 3.0% |
| Return on assets | 29.5% | 10.0% |
| Equity ratio | 73.9% | 36.3% |
| Debt-to-equity | 0.35 | 1.52 |
| Current ratio | 3.84 | 1.73 |
| Revenue growth | −5.2% | 5.7% |
The median and “ahead of” refer to companies in the Morning class Small in the same sector in 2025. The bar shows the share of companies the figure is ahead of.
With an index of 76, AME BIOSCIENCE AS does better than 94% of companies in the Morning class Small in the same sector (7,421 companies) in 2025.
Score 2023–2025
- AME BIOSCIENCE AS
- Median: companies in the Morning class Small in the same sector
AME BIOSCIENCE AS has a score of 76 for 2025, rank 1,433 of 23,059 in the sector.
Strongest: Profitability: percentile 91 against peers, operating margin 20.2% against a median of 3.4%. Solidity: percentile 89 against peers, equity ratio 73.9% against a median of 36.3%.
Weakest: Growth: percentile 20 against peers, revenue growth −5.2% against a median of 5.7%.
Worth a closer look
- What lies behind weak growth, and will it last?
Written by fixed rules from the figures. Describes the figures, does not explain causes. Not investment or financial advice. How the summary is made
What the numbers say
AME BIOSCIENCE AS had an operating margin of 20.2% and an equity ratio of 73.9% in 2025, and ranks 1,433 of 23,059 in Handel.
From 2024 to 2025: the equity ratio rose from 63.5% to 73.9%.
This text is generated automatically from the 2025 accounts.
Three simple methods
The methods give between 9 MNOK and 39 MNOK.
| Method | Multiple | Estimate |
|---|---|---|
| P/E | 10.0 | 28 MNOK |
| EV/EBIT | 8.0 | 39 MNOK |
| P/B | 1.0 | 9 MNOK |
A mechanical estimate from public accounts, not advice. Mechanical estimate from public accounts with fixed multiples. Not a valuation and not advice to buy or sell. The multiples are provisional default values and must be adjusted per sector before the figures are used for anything. See the calculation
Worth a closer look
- positive
Upper quartile on profitability, solidity and liquidity. What sets this company apart from the rest of the sector?
Based on: Operating margin 20.2% (median 3.4%); Equity ratio 73.9% (median 36.3%); Current ratio 3.84 (median 1.73).
Indications based on the latest annual accounts from open data. Not investment or financial advice.
Financial costs were 1.5% of the debt in 2025. The policy rate averaged 4.30 % the same year. This is a plain description of what the debt cost, not a model of interest sensitivity.
See interest rates, prices and exchange rates for the sector
Data quality
No anomalies found in the figures.
Scenario analysis: the sector's weakest year
We have no accounts for 2022, the sector's weakest year, for this company.
The sector's weakest year was 2022, with a median operating margin of 1.5%. Based on the 11 fiscal years we have. The analysis grows as more years are fetched or imported. Methodology
What the score is made of
| Profitability | 91 | weight 30% |
|---|---|---|
| Solidity | 89 | weight 25% |
| Liquidity | 87 | weight 15% |
| Growth | 20 | weight 15% |
| Consistency | 72 | weight 15% |
Durability: 82 (average over 3 years)
Index version 2. Data completeness 100%: the share of the weights that had data.
Questions and answers
How profitable is AME BIOSCIENCE AS?
The operating margin was 20.2% in 2025, against a median of 3.4% among companies in the Morning class Small in the same sector. Return on assets was 29.5%.
How solid is AME BIOSCIENCE AS?
The equity ratio was 73.9% in 2025 (median 36.3%). Debt-to-equity was 0.35 (median 1.52).
What is the liquidity of AME BIOSCIENCE AS like?
The current ratio was 3.84 in 2025 (median 1.73).
How does AME BIOSCIENCE AS compare in Handel?
AME BIOSCIENCE AS ranks 1,433 of 23,059 in Handel for 2025. Among companies in the Morning class Small it is number 438 of 7,421. Revenue changed by −5.2% from the year before.
From the Central Coordinating Register
- Org. no.
- 988736899
- Legal form
- AS
- Sector
- Handel (46.640)
- Morning company class
- Small
- Employees
- 0–4 (not registered)
- Founded
- 10 September 2005 21 years in operation
- Share capital
- 0.10 MNOK
- Business address
- Husvikveien 165, 3124 TØNSBERG
- Municipality
- Tønsberg rank 2 of 10 in KOSTRA group 11
- Latest accounts filed
- 2025
- Website
- www.amebioscience.com
Source: Central Coordinating Register, Brønnøysund Register Centre. The employee count is reported by the company and may be older than the accounts. See the company at the Brønnøysund Register Centre
Ownership and roles
- Chief executive
- Alister Martin Ewing
- Chair of the board
- Alister Martin Ewing
- Deputy member
- Inger Ronander
- Auditor
- REVISJONSFIRMAET HOTVEDT & CO AS
- Accountant
- AMESTO ACCOUNTHOUSE SØR AS
Source: Central Coordinating Register, fetched 29 October 2026. Only names are shown.
Owners and shareholdings will appear here once the shareholder data extract is in place.
Coming · not built yet
Error in the data?
Do you see an error in the figures or in how the company is mapped (sector, holding, group)? Let us know. Corrections require documentation.
Figures last fetched 29 October 2026.
Year by year · 2023–2025
| Key figure | 2023 | 2024 | 2025 | Trend |
|---|---|---|---|---|
| Index | 86 | 83 | 76 | |
| Rank | 909 | 555 | 1,433 | |
| Operating margin | 18.8% | 20.2% | 20.2% | |
| Return on assets | 21.0% | 38.6% | 29.5% | |
| Equity ratio | 76.6% | 63.5% | 73.9% | |
| Current ratio | 4.27 | 2.74 | 3.84 | |
| Revenue growth | – | 232.2% | −5.2% |
Accounts
From the Brønnøysund Register Centre, in the company's reporting currency (NOK).
| Key figure | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating revenue | 5.8 MNOK | 19.3 MNOK | 18.3 MNOK |
| Operating profit | 1.1 MNOK | 3.9 MNOK | 3.7 MNOK |
| Profit before tax | 1.1 MNOK | 3.9 MNOK | 3.7 MNOK |
| Net profit | 0.8 MNOK | 3.0 MNOK | 2.8 MNOK |
| Financial expenses | 0.0 MNOK | 0.0 MNOK | 0.1 MNOK |
| Total assets | 5.3 MNOK | 10.1 MNOK | 12.6 MNOK |
| Current assets | 5.3 MNOK | 10.1 MNOK | 12.6 MNOK |
| Equity | 4.1 MNOK | 6.4 MNOK | 9.3 MNOK |
| Retained earnings | 3.9 MNOK | 6.3 MNOK | 9.2 MNOK |
| Total liabilities | 1.2 MNOK | 3.7 MNOK | 3.3 MNOK |
| Current liabilities | 1.2 MNOK | 3.7 MNOK | 3.3 MNOK |
Source: Brønnøysund Register Centre (Register of Company Accounts), fetched 29 October 2026, accounts id 6984536.
Further
Similar companies
- SAMI SHOP AS index 76, rank 1,431 · compare
- ROBUR SAFE AS index 76, rank 1,432 · compare
- IBILN AS index 76, rank 1,437 · compare
- STRANDEN GLOBAL AS index 76, rank 1,440 · compare
- GULLSMED A G HAAKONSEN AS index 76, rank 1,445 · compare